$1,200,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments. Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals. Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit. Education about non-opioid pain therapies and patient access to non-opioid medicines, updates on coverage progress at the VHA and CMS. Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37). Issues related to the Defense Health Agency and service member access to non-opioid alternatives, including reinstating the DHA Benefits Advisory Panel and the structured formulary management process. Issues related to Sec. 232 pharmaceutical tariffs, onshoring active pharmaceutical ingredients (API), and supply chain disruptions for products related to the opioid public health emergency."
You can find more data on corporate lobbying on Quiver Quantitative.
VRTX Congressional Stock Trading
Members of Congress have traded $VRTX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAVID TAYLOR sold up to $15,000 on 01/29.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
VRTX Insider Trading Activity
VRTX insiders have traded $VRTX stock on the open market 50 times in the past 6 months. Of those trades, 0 have been purchases and 50 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:
- AMIT SACHDEV (EVP Chief Patient & Ext Af Off) has made 0 purchases and 9 sales selling 60,459 shares for an estimated $28,377,385.
- CARMEN BOZIC (EVP and CMO) has made 0 purchases and 7 sales selling 19,069 shares for an estimated $8,685,637.
- DUNCAN MCKECHNIE (EVP, Chief Commercial Officer) has made 0 purchases and 5 sales selling 11,521 shares for an estimated $5,664,789.
- JONATHAN BILLER (EVP and Chief Legal Officer) has made 0 purchases and 5 sales selling 7,578 shares for an estimated $3,640,101.
- MARK E. BUNNAGE (EVP, Chief Scientific Officer) has made 0 purchases and 4 sales selling 6,260 shares for an estimated $2,984,769.
- EDWARD MORROW III ATKINSON (EVP, Chief Technical Ops. Off.) has made 0 purchases and 4 sales selling 5,267 shares for an estimated $2,512,184.
- OURANIA TATSIS (EVP, Chief Reg. & Quality Off.) has made 0 purchases and 6 sales selling 4,703 shares for an estimated $2,350,876.
- JOY LIU (EVP and Chief Legal Officer) has made 0 purchases and 5 sales selling 4,630 shares for an estimated $2,131,396.
- KRISTEN AMBROSE (SVP & Chief Accounting Officer) has made 0 purchases and 3 sales selling 1,956 shares for an estimated $914,567.
- SANGEETA N. BHATIA has made 0 purchases and 2 sales selling 584 shares for an estimated $267,746.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
VRTX Hedge Fund Activity
We have seen 744 institutional investors add shares of VRTX stock to their portfolio, and 639 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS added 3,809,620 shares (+22.0%) to their portfolio in Q1 2026, for an estimated $1,692,499,877
- WINSLOW CAPITAL MANAGEMENT, LLC removed 887,640 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $394,351,822
- GOLDMAN SACHS GROUP INC added 664,473 shares (+37.9%) to their portfolio in Q1 2026, for an estimated $295,205,419
- WELLINGTON MANAGEMENT GROUP LLP removed 609,142 shares (-15.9%) from their portfolio in Q1 2026, for an estimated $270,623,516
- ALLIANCEBERNSTEIN L.P. removed 585,696 shares (-13.0%) from their portfolio in Q1 2026, for an estimated $260,207,161
- PRICE T ROWE ASSOCIATES INC /MD/ removed 518,836 shares (-22.8%) from their portfolio in Q1 2026, for an estimated $230,503,269
- JENNISON ASSOCIATES LLC removed 509,482 shares (-15.7%) from their portfolio in Q1 2026, for an estimated $226,347,568
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
VRTX Analyst Ratings
Wall Street analysts have issued reports on $VRTX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 03/18/2026
- HC Wainwright & Co. issued a "Buy" rating on 02/13/2026
To track analyst ratings and price targets for VRTX, check out Quiver Quantitative's $VRTX forecast page.
VRTX Price Targets
Multiple analysts have issued price targets for $VRTX recently. We have seen 17 analysts offer price targets for $VRTX in the last 6 months, with a median target of $572.0.
Here are some recent targets:
- Brian Skorney from Baird set a target price of $350.0 on 07/07/2026
- Brian Abrahams from RBC Capital set a target price of $570.0 on 07/07/2026
- Eliana Merle from Barclays set a target price of $615.0 on 05/06/2026
- Terence Flynn from Morgan Stanley set a target price of $616.0 on 05/05/2026
- William Pickering from Bernstein set a target price of $572.0 on 05/05/2026
- Whitney Ijem from Canaccord Genuity set a target price of $436.0 on 05/05/2026
- Naz Rahman from Maxim Group set a target price of $575.0 on 03/18/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
